首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1573708

苯酮尿症 (PKU) 治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032 年

Phenylketonuria (PKU) Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月27日 | 出版商:

Global Market Insights Inc. | 英文 223 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球苯酮尿症(PKU) 治療市場價值為7.377 億美元，預計2024 年至2032 年複合年成長率為7.2%。。

加強新生篩檢措施有助於早期檢測 PKU，從而增加對有效管理療法的需求。同時，積極的研究和開發正在產生創新的治療方案，包括基因療法和新型藥物製劑，有望改善患者的治療效果。例如，2023 年 11 月，賓州大學佩雷爾曼醫學院公佈了使用先進 CRISPR 基因編輯技術（特別是引子和鹼基編輯）進行未來治療的研究。這些進步有望在基因醫學領域引入突破性的療法。此外，醫療保健專業人員和患者對及時、持續治療的好處的認知不斷提高，進一步推動了 PKU 治療市場的發展。

整個苯酮尿症治療市場根據 PKU 類型、治療類型、年齡層、給藥途徑、最終用戶和地區進行分類。

預計到 2032 年，經典 PKU 細分市場的複合年成長率將達到 7%。嚴格的飲食控制和持續監測對於經典 PKU 患者至關重要。這種形式的 PKU 推動了對膳食補充劑、藥物和新興療法等治療的需求。廣泛的管理需求和龐大的患者群體導致市場專注於有效調節苯丙胺酸水平並預防長期併發症的解決方案。

2023年，藥物治療成為主導細分市場，佔54.5%的市場。這種突出的原因是藥物治療在治療 PKU 方面發揮著至關重要的作用，特別是對於僅透過飲食措施難以維持控制的患者而言。包括沙丙蝶呤二鹽酸鹽和其他新興療法在內的藥物在降低血液苯丙胺酸水平方面發揮著至關重要的作用，從而顯著改善患者的預後。標靶藥物治療的不斷擴大和藥物治療的進步正在解決未滿足的需求並增加市場需求。此外，這些藥物療法補充了飲食管理，為 PKU 患者提供了更全面、更具適應性的治療方案。

2023年，美國苯酮尿症治療市場價值為2.806億美元，預計到2032年將達到5.025億美元。基因檢測和專業醫療食品的創新正在徹底改變北大的管理，強調早期檢測和個人化治療策略。新一代定序等先進技術的整合正在提高基因檢測的準確性並增強飲食管理產品。這些技術進步不僅提高了治療效果，也為美國市場參與者創造了利潤豐厚的機會

產業生態系統分析
產業影響力
- 成長動力
  - PKU 盛行率上升
  - PKU新療法的進展
  - 加強新生兒篩檢計劃
  - 提高早期篩檢和治療的意識
- 產業陷阱與挑戰
  - 嚴格的監管要求
成長潛力分析
報銷場景
管道分析
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按北大類型，2021 - 2032

主要趨勢
經典北大
輕度苯酮尿症
中度或變異型 PKU
高苯丙胺酸血症

第 6 章：市場估計與預測：按治療類型，2021 - 2032 年

主要趨勢
藥物治療
飲食管理
其他治療類型

第 7 章：市場估計與預測：按年齡分類，2021 - 2032

主要趨勢
兒科
成年人

第 8 章：市場估計與預測：按管理途徑，2021 - 2032 年

主要趨勢
口服
注射用

第 9 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

主要趨勢
醫院
專科診所
其他最終用戶

第 10 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 11 章：公司簡介

Abbott Laboratories
American Gene Technologies
APR Applied Pharma Research s.a.
BioMarin Pharmaceutical Inc.
Codexis, Inc.
Erytech Pharma SA
Homology Medicines, Inc.
Lysogene S.A.
PIAM Farmaceutici S.P.A.
Pluvia AS
PTC Therapeutics
SOM Innovation Biotech SL
Synlogic
Ultragenyx (Dimension Therapeutics)
Vitaflo International Ltd.

簡介目錄

Product Code: 11037

The Global Phenylketonuria (PKU) Treatment Market was valued at USD 737.7 million in 2023 and is projected to expand at a CAGR of 7.2% from 2024 to 2032. The rising demand for PKU treatments is driven by a global increase in PKU cases and advancements in treatment methods.

Enhanced newborn screening initiatives facilitate earlier PKU detections, boosting the demand for effective management therapies. Concurrently, active research and development are producing innovative therapeutic options, including gene therapy and novel drug formulations, which promise improved patient outcomes. For instance, in November 2023, the Perelman School of Medicine at the University of Pennsylvania unveiled research on future treatments using advanced CRISPR gene editing techniques, specifically prime and base editing. These advancements are poised to introduce groundbreaking therapies in genetic medicine. Moreover, increased awareness among healthcare professionals and patients about the benefits of timely and sustained treatment is further driving the PKU treatment market.

The overall phenylketonuria treatment market is classified based on PKU type, treatment type, age group, route of administration, end-user, and region.

Classic PKU segment is estimated to grow at a 7% CAGR through 2032. Its prevalence and the necessity for lifelong management underscore its market dominance. Stringent dietary controls and constant monitoring are essential for classic PKU patients. This form of PKU drives the demand for treatments like dietary supplements, medications, and emerging therapies. The extensive management needs and sizable patient population lead to a market focus on solutions that effectively regulate phenylalanine levels and prevent long-term complications.

In 2023, drug therapy emerged as the leading segment, capturing a market share of 54.5%. This prominence is due to drug therapy's crucial role in managing PKU, especially for patients who struggle to maintain control through dietary measures alone. Medications, including sapropterin dihydrochloride and other emerging therapies, play a vital role in lowering blood phenylalanine levels, leading to significant improvements in patient outcomes. The expanding availability of targeted drug therapies and advancements in pharmacological treatments are addressing unmet needs and increasing market demand. Furthermore, these drug therapies complement dietary management, fostering more comprehensive and adaptable treatment regimens for PKU patients.

In 2023, the U.S. phenylketonuria treatment market was valued at USD 280.6 million, with projections pointing towards USD 502.5 million by 2032. This robust growth is largely due to breakthroughs in diagnostic and therapeutic technologies. Innovations in genetic testing and specialized medical foods are revolutionizing PKU management, emphasizing early detection and personalized treatment strategies. The integration of advanced technologies, like next-generation sequencing, is refining genetic testing accuracy and enhancing dietary management products. These technological strides not only bolster treatment outcomes but also create lucrative opportunities for the market players in the U.S.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of PKU
  - 3.2.1.2 Advancements in new therapies for PKU
  - 3.2.1.3 Enhanced newborn screening programs
  - 3.2.1.4 Growing awareness for early screening and treatment
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Reimbursement scenario
3.5 Pipeline analysis
3.6 Regulatory landscape
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By PKU Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Classic PKU
5.3 Mild PKU
5.4 Moderate or variant PKU
5.5 Hyperphenylalaninemia

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Drug therapy
6.3 Dietary management
6.4 Other treatment types

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Pediatrics
7.3 Adults

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Oral
8.3 Parenteral

Chapter 9 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospitals
9.3 Specialty clinics
9.4 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa